College of Pharmacy Faculty Research ​and Publications

The Discovery of the MCH-1 Receptor Antagonist NGD-4715 for the Potential Treatment of Obesity

Document Type

Book Chapter

Publication Title

Comprehensive Medicinal Chemistry III

Publication Date

6-2017

Volume

8

First Page

488

Last Page

515

Abstract

For the first time, we disclose the medicinal chemistry efforts at Neurogen Corporation that led to the discovery of the clinical phase I compound NGD-4715 ( 7 ), a selective, brain penetrant, orally bioavailable melanin-concentrating hormone receptor 1 antagonist. We discuss the optimization of an arylpiperazine serendipitous hit in a high-throughput screening that led to the discovery of NDT 9522320 ( 10 ), a useful tool compound that enabled target validation in rat and dog feeding models. Subsequent medicinal chemistry design led to the bicyclic core of NGD-4715. We recount how we arrived at selecting NGD-4715 as a development candidate and summarize our clinical experience with it. A number of syntheses are presented, which were explored as a prelude to the highly optimized chemical process synthesis used to support the IND-enabling toxicology program and deliver clinical supplies for the phase I studies. We discuss the backup strategy that led to NGD-0589, as well as the discovery of further improved compounds.

Creative Commons Usage License

All Rights Reserved

Copyright held by

Elsevier Ltd

Link to Full Text

Share

COinS